NCT05113017招募中不适用
To Evaluate the Effectiveness and Safety of Stereotactic Radiotherapy (SBRT) in the Treatment of Patients With Residual Malignant Pulmonary Nodules After Lung Cancer Surgery: A Multi-center, Prospective Clinical Trial (SMILE)
Fang Wu5 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 5
- 主要终点
- Local control rate of cancer of SBRT
研究概览
简要总结
To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary malignant pulmonary nodules who cannot tolerate multiple operations.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) Age 18-75 years old; (2) ECOG score 0-2 points; (3) Chest CT showed at least two lung nodules (pure ground glass, partial solid or solid nodules); (4) At least one lesion has been pathologically diagnosed as lung cancer (T1N0M0-T1N1M0); (5) At least one residual pulmonary nodule has been diagnosed pathologically or multidisciplinary diagnosis and treatment (MDT) discussed and considered as a primary malignant pulmonary nodule; (6) The residual lung nodules are inoperable or operable but the patient refuses to be surgically removed; (7) Have self-consciousness and can sign informed consent; (8) Must be able to swallow tablets.
排除标准
- •(1) There are metastatic pulmonary nodules; (2) Have received chest radiotherapy in the past; (3) Lymph node metastasis or distant metastasis; (4) The tumor is located in the proximal bronchial tree area. The proximal bronchial tree is defined as carina, left and right main bronchus, left and right upper lobe bronchus, middle bronchus, right middle lobe bronchus, lingual bronchus, left and right lower lobe bronchi; the proximal bronchial tree area is defined as surrounding the proximal bronchial tree in all directions The area within 2cm above; (5) Pneumonectomy patients; (6) Severe primary diseases such as heart, liver, kidney, hematopoietic system, etc.; (7) Women during pregnancy and lactation; (8) Active period of the human immunodeficiency virus (HIV) infection; (9) Those with active systemic infection, pneumonia, tuberculosis, and pericarditis; (10) There is a history of psychotropic drug abuse or drug abuse;(11)Insulin dependent diabetes;(12) Thyroid disease
结局指标
主要结局
Local control rate of cancer of SBRT
时间窗: 2-year
Local control rate of cancer
Incidence of Treatment-Emergent Adverse Events of SBRT [Safety and Tolerability]
时间窗: 2-year
Treatment-related adverse event
次要结局
- OS(2-year)
- Survival(2-year)
- PFS(2-year)
研究者
Fang Wu
Clinical Associate Professor
Second Xiangya Hospital of Central South University
研究点 (5)
Loading locations...
相似试验
已完成
不适用
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian CancerOvarian NeoplasmsRecurrent Ovarian CarcinomaOligometastatic DiseaseNCT04593381Gemelli Molise Hospital376
尚未招募
2 期
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLCNon-Small-Cell Lung CancerNCT06434740Sir Run Run Shaw Hospital37
招募中
不适用
Prospective Observational Basket Study of Stereotactic Body Radiation Therapy for OligoMetastatic Patients From Rare TumorsOligometastatic DiseaseNCT05903261Istituto Clinico Humanitas200
尚未招募
不适用
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)EGF-R Positive Non-Small Cell Lung CancerNon Small Cell Lung CancerEGFR Exon 19 DeletionEGFR Exon 21 MutationEGFR G719XNCT05998993Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo35
招募中
不适用
Focal Radiotherapy for Previously Treated Prostate Cancer PatientsLocally Recurrent Prostate CancerNCT03073278Royal North Shore Hospital36